Statement by WHO Regional Director on health needs in Syria
21 September 2022 – Over the past 3 days during my visit here in Damascus and to Daraa governorate, I have seen firsthand the devastating impact of war, economic instability and sanctions on innocent Syrians whose health even now continues to deteriorate. In Daraa, once a hotspot of intense fighting and where parts of the governorate still remain in ruins, I met an elderly lady undergoing dialysis treatment who burst into tears as she spoke to me about her medical condition, and the fate that had befallen her country. Sobbing, she turned to me and asked, “What has happened to us?” It was a hard question for me to a...
Source: WHO EMRO News - September 21, 2022 Category: Middle East Health Source Type: news

TREMFYA ®▼ (guselkumab) Demonstrates Higher Rates of Complete Skin Clearance with Earlier Treatment in Adults with Moderate to Severe Plaque Psoriasis in Phase 3b GUIDE Study
Beerse, Belgium, 8 September 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data for TREMFYA®▼(guselkumab) from the ongoing Phase 3b GUIDE study, which is designed to understand the impact of early intervention and potential dosing interval flexibility on the long-term disease course in adult patients with moderate to severe plaque psoriasis (Pso). These new data demonstrated that “super responders”a to guselkumab who received every-16-week dosingb maintained disease control (absolute Psoriasis Area and Severity Index [PASI] score <3) at a rate that was non-inferior to ...
Source: Johnson and Johnson - September 8, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

Uganda: Efforts to Address Vitamin A Deficiency Miss the Mark
[The Conversation Africa] Vitamin A deficiency is the leading cause of preventable childhood blindness. It also increases the risk of death from common childhood illnesses such as diarrhoea. There are several ways to fight this public health threat: giving children vitamin A supplements; promoting more diverse diets; fortifying food; and bio-fortifying crops. Nutrition campaigns can go with these efforts. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - August 23, 2022 Category: African Health Source Type: news

Nigeria: Federal Govt Introduces Vaccine to Fight 50,000 Diarrhoea Deaths Annually
[Leadership] Federal government has said that about 50,000 deaths occur in children under five years in Nigeria as a result of rotavirus infection, saying vaccination against the virus will avert these deaths. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - August 23, 2022 Category: African Health Source Type: news

South Africa: Mother Dead, Scores Sick With Diarrhoea As Polluted Tap Water Confirmed
[Daily Maverick] In response to questions from Our Burning Planet after the death of Rashnie Baijnath, the eThekwini Municipality confirmed that tap water in the Birchwood area, west of the city, 'does not meet acceptable standards for human consumption'. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - August 22, 2022 Category: African Health Source Type: news

Gambia: Mayoress Lowe Extends Magnanimity to Banjul Flood Victims As Cases of Diarrhoea Reported
[The Point] Rohey Malick Lowe, the mayoress of Banjul over the weekend embarked on a series of visits to flood victims in Banjul amid the heavy downpour. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - August 10, 2022 Category: African Health Source Type: news

European Commission Approves IMBRUVICA ® (ibrutinib) in a Fixed-Duration Combination Regimen for Adult Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)
BEERSE, BELGIUM, 4 August 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission granted marketing authorisation for the expanded use of IMBRUVICA® (ibrutinib) in an all-oral, fixed-duration (FD) treatment combination with venetoclax (I+V) for adults with previously untreated chronic lymphocytic leukaemia (CLL). The approval is based on the pivotal Phase 3 GLOW study that demonstrated superior progression-free survival (PFS) in patients treated with I+V versus chlorambucil-obinutuzumab (Clb+O), and the FD cohort of the Phase 2 CAPTIVATE study, which showed deep ...
Source: Johnson and Johnson - August 4, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

Malawi: Poor Sanitation Accounts for 52 Percent of the Total Disease Burden in Malawi
[Nyasa Times] Poor sanitation accounts for 52 percent of the total disease burden in Malawi, with diarrhoea alone accounting for seven per cent of under-five deaths, latest statistics have shown. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - July 28, 2022 Category: African Health Source Type: news

Vitamin D overdose warning: How you can actually take too much of something so good
The middle-aged patient, from Kent, lost two stone in three months after suffering from constant vomiting, diarrhoea and stomach pains. He had been taking a cocktail of supplements. (Source: the Mail online | Health)
Source: the Mail online | Health - July 7, 2022 Category: Consumer Health News Source Type: news

You can overdose on vitamin D
The middle-aged patient, from Kent, lost two stone in three months after suffering from constant vomiting, diarrhoea and stomach pains. He had been taking a cocktail of supplements. (Source: the Mail online | Health)
Source: the Mail online | Health - July 5, 2022 Category: Consumer Health News Source Type: news

New shipment of WHO health supplies for Afghanistan earthquake response delivered to Kabul from ...
28 June 2022 – A flight containing 25 metric tonnes of WHO health supplies has just landed in Kabul from WHO’s logistics hub in Dubai to support the Afghanistan earthquake response. The shipment includes enough essential medicines, trauma and surgical supplies, and other critical health supplies for almost 400 000 people in need of health care services, including 1500 trauma patients and 2750 suspected cases of acute watery diarrhoea. “WHO is grateful for the continued support of His Highness Sheikh Mohammed bin Rashid Al Maktoum, the Vice President and Prime Minister of the United Arab Emirates, and Ruler of Dubai...
Source: WHO EMRO News - June 28, 2022 Category: Middle East Health Source Type: news

Viruses survive in fresh water by ‘hitchhiking’ on plastic, study finds
Intestinal viruses such as rotavirus were found to be infectious for up to three days by attaching to microplastics, research showsDangerous viruses can remain infectious for up to three days in fresh water by hitchhiking on plastic, researchers have found.Enteric viruses that cause diarrhoea and stomach upsets, such as rotavirus, were found to survive in water by attaching to microplastics, tiny particles less than 5mm long. They remain infectious, University of Stirling researchers found, posing a potential health risk.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - June 27, 2022 Category: Science Authors: Karen McVeigh Tags: Plastics Environment Health Oceans Pollution Society Biology Science Microbiology Source Type: news

Janssen Receives Positive CHMP Opinion for IMBRUVICA ® (ibrutinib) in a Fixed-Duration Combination Regimen for Adult Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)
BEERSE, BELGIUM, June 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending approval of a new treatment option with IMBRUVICA® (ibrutinib) in an oral fixed-duration combination with venetoclax (I+V) for adults with previously untreated chronic lymphocytic leukaemia (CLL). Outcomes for patients with CLL have improved in the last decade with the advent of oral therapies that target the underlying disease biology.[1] This provides the opportunity...
Source: Johnson and Johnson - June 24, 2022 Category: Pharmaceuticals Source Type: news

European Commission Grants Conditional Approval of CARVYKTI ® (Ciltacabtagene Autoleucel), Janssen’s First Cell Therapy, for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
BEERSE, BELGIUM, 26 May 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission (EC) granted conditional marketing authorisation of CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed and refractory multiple myeloma (RRMM) who have received at least three prior therapies, including an immunomodulatory agent (IMiD), a proteasome inhibitor (PI) and an anti-CD38 antibody, and have demonstrated disease progression on the last therapy. In December 2017, Janssen Biotech, Inc. (Janssen) entered into an exclusive worldwide license a...
Source: Johnson and Johnson - May 26, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Roche ’s Polivy combination approved by European Commission for people with previously untreated diffuse large B-cell lymphoma
First new treatment option in more than 20 years to show a clinically meaningful improvement in progression-free survival is approved for people with previously untreated diffuse large B-cell lymphoma (DLBCL)Approval is based on pivotal data from the phase III POLARIX study, where Polivy plus R-CHP significantly improved progression-free survival with comparable safety versus the standard of care, R-CHOPFirst-line treatment with Polivy plus R-CHP has the potential to reduce the burden on patients and healthcare systems, associated with disease progression ¹Basel, 25 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today anno...
Source: Roche Investor Update - May 25, 2022 Category: Pharmaceuticals Source Type: news